

AD _____

Award Number: W81XWH-08-1-0327

TITLE: Catecholamines in post-traumatic stress disorder

PRINCIPAL INVESTIGATOR: Steven A. Thomas

CONTRACTING ORGANIZATION: University of Pennsylvania
Philadelphia, PA 19104-6084

REPORT DATE: July 2012

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

*Form Approved
OMB No. 0704-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE July 2012			2. REPORT TYPE Final		3. DATES COVERED 1 July 2008 – 30 June 2012	
4. TITLE AND SUBTITLE Catecholamines in post-traumatic stress disorder			5a. CONTRACT NUMBER			
			5b. GRANT NUMBER W81XWH-08-1-0327			
			5c. PROGRAM ELEMENT NUMBER			
6. AUTHOR(S) Steven A. Thomas E-Mail: sathomas@upenn.edu			5d. PROJECT NUMBER			
			5e. TASK NUMBER			
			5f. WORK UNIT NUMBER			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pennsylvania Philadelphia, PA 19104-6084					8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012					10. SPONSOR/MONITOR'S ACRONYM(S)	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited						
13. SUPPLEMENTARY NOTES						
14. ABSTRACT The purpose of these studies is to test the hypothesis that adrenergic and dopaminergic signaling contribute to consolidation (and possibly reconsolidation) of fear memory in a redundant manner by stimulation of β 2-adrenergic and the D1-class of dopaminergic receptors in the basolateral amygdala. Combined pharmacologic and genetic studies in mice have examined the above hypothesis for the consolidation of fear memory. The results are in agreement with the hypothesis. Roles for these signaling pathways in reconsolidation are not as clear, as combined treatment does not appear to influence reconsolidation. Current results indicate that treatment with β -adrenergic receptor antagonists (β blockers) alone shortly after trauma is unlikely to prevent the development of PTSD. However, combination therapy of β blockers and D1 receptor antagonists shortly after trauma may reduce the incidence of PTSD.						
15. SUBJECT TERMS Fear, memory, consolidation, norepinephrine, dopamine, amygdala						
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC	
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U	UU	16	19b. TELEPHONE NUMBER (include area code)	

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusion.....	5
References.....	6
Appendices.....	6

Introduction

The objectives of the proposed studies are to better define the underlying mechanisms that lead to PTSD, and to use this understanding to develop pharmacologic therapies that will prevent the development of PTSD in at risk individuals, as well as to ameliorate symptoms of PTSD in those that already have it. A widely held hypothesis is that activation of adrenergic signaling in certain brain regions greatly strengthens memories of traumatic events. It is also hypothesized that excessive adrenergic signaling following trauma could lead to memories that are too strong, contributing to the recurrent, intrusive retrieval of the traumatic events that occurs in PTSD. As a result, it has been proposed that pharmacologically interfering with adrenergic signaling may prevent or ameliorate PTSD. However, our and other studies demonstrate that interfering with β -adrenergic signaling does not reduce fear memory formation or persistence. We hypothesize that fear memory formation and persistence are mediated by redundant signaling systems that include β -adrenergic signaling and signaling by dopamine within the basolateral amygdala, and that these two signaling pathways utilize similar intracellular processes.

Body

All of the aims are complete. Results for Aim 1 (Do the adrenergic and dopaminergic systems contribute redundantly to fear memory consolidation?) and the consolidation portions of Aims 3 (Do the adrenergic and dopaminergic systems mediate consolidation/reconsolidation in the amygdala?) and Aim 4 (Are the adrenergic and dopaminergic systems redundant for consolidation/reconsolidation because they both activate extracellular signal-regulated kinase (ERK) signaling?) are reported in a paper published this year in the Journal of Neuroscience. This paper is included in the Appendix and is listed as #6 in References below.

Aim 2 (Do the adrenergic and dopaminergic systems contribute redundantly to fear memory reconsolidation?) provided negative results shown in Figure 1 below. As a result, the reconsolidation portions of Aims 3 & 4 were not pursued.




Figure 1. Reconsolidation of cued fear conditioning is unaffected by NE deficiency, β receptor blockade, or combination β_2 / D_{1,5} antagonism. **A)** $Dbh^{+/+}$ and $Dbh^{-/-}$ mice were injected with saline (Sal) or the protein synthesis inhibitor anisomycin (Ani, 150 mg/kg) 30 min before testing on Day 1. As expected, anisomycin impaired reconsolidation, and this was independent of genotype. However, Sal-treated $Dbh^{-/-}$ mice that completely lack NE/E exhibit normal reconsolidation. $P < 0.01$ for the interaction of treatment and day. $^P < 0.01$ for saline versus anisomycin on Day 2. **B)** WT mice were injected with Sal or various doses (mg/kg) of the β receptor blocker propranolol (Prop) immediately after testing on Day 1. Reconsolidation was not impaired in any of the Prop-treated groups. **C)** To test whether β_2 receptor signaling might be redundant with D_{1,5} dopamine signaling in reconsolidation, WT mice were injected with either Sal, the β_2 antagonist ICI 118,551 (ICI, 30 μ g/kg), the D_{1,5} antagonist SCH 23390 (SCH, 30 μ g/kg) or the combination of ICI and SCH. Neither the individual treatments nor the combination treatment affected reconsolidation.

Key Research Accomplishments

- Either NE or DA is sufficient for the consolidation of auditory cued fear memory in mice and rats. These neurotransmitters appear to act in a redundant manner.
- NE exerts its effects by signaling through β_2 receptors, while DA does so through D₅ receptors.
- Redundant fear memory consolidation (NE and DA) occurs in the basolateral amygdala.
- Contrary to initial predictions, neither β_2 nor D₅ signal through the G protein G_s to promote fear memory consolidation, nor does their signaling intersect at the level of ERK (extracellular signal-regulated kinase) activation. Instead, we have now found that D₅ signals through G_q and β_2 signals through G_i. Interestingly, these signaling mechanisms rapidly converge to activate phospholipase C, which generates the second messengers diacylglycerol and inositol trisphosphate.
- The D_{1/5} receptor antagonist ecopipam, used previously in human clinical trials, is effective at reducing fear memory consolidation when combined with a β receptor blocker.

Reportable Outcomes

- 1) A manuscript reporting the above results was published in February, 2012 in the Journal of Neuroscience (Ouyang et al., see Appendix).

Conclusions

- Results suggest that administration of β blockers alone shortly after trauma will not prevent the development of PTSD.
- However, low dose combination therapy with β_2 & D₅ receptor antagonists might prevent the development of PTSD when given shortly after trauma.
- Unfortunately, such a combination may not aid in the treatment of established PTSD because it did not have an effect in animal models examining the reconsolidation of fear memory.

Personnel with Effort

- Steven A. Thomas, MD, PhD. Title: Principle Investigator
- Ming Ouyang, PhD. Title: Senior Research Investigator.
- Matthew B. Young, BS. Title: Graduate Research Assistant
- Melissa M. Lestini, MD, PhD. Title: Neonatology Research Fellow

References

- 1) Ouyang M, Murray M and Thomas SA (2009) Redundant Catecholaminergic Signaling in the Consolidation of Fear Memory. Military Health Research Forum, Abstract S3-6/P19-8.
- 2) Ouyang M, Murray M and Thomas SA (2009) Monoamines, Memory and Mouse PTSD. Gordon Research Conference on Catecholamines; Biddeford, ME
- 3) Ouyang M, Murray M and Thomas, SA (2010) Redundant catecholaminergic signaling in the consolidation of fear memory. Society for Neuroscience Abstract 915.20; San Diego, CA.
- 4) Young MB, Ouyang M and Thomas, SA (2011) Consolidation of cued fear memory requires phospholipase C activation by either β_2 -adrenergic or D_5 -dopaminergic receptors in the basolateral amygdala. Society for Neuroscience Abstract 837.18; Washington, DC
- 5) Thomas, SA, Ouyang M, Schutsky K, Young MB, Castelino, CB, Zhang L and Lestini MM (2012) Catecholamines in Cognition: Novel Signaling Mechanisms in Memory Consolidation and Retrieval during Stress. Genes, Brain & Behavior Meeting, Abstract 62; Boulder, CO.
- 6) Ouyang M, Young, MB, Lestini MM, Schutsky K and Thomas SA (2012) Redundant Catecholamine Signaling Consolidates Fear Memory via Phospholipase C. Journal of Neuroscience 32: 1932-1941. PMC3306178.

Appendices

- 1) Ouyang M, Young, MB, Lestini MM, Schutsky K and Thomas SA (2012) Redundant Catecholamine Signaling Consolidates Fear Memory via Phospholipase C. Journal of Neuroscience 32: 1932-1941. PMC3306178.

Redundant Catecholamine Signaling Consolidates Fear Memory via Phospholipase C

Ming Ouyang,¹ Matthew B. Young,¹ Melissa M. Lestini,² Keith Schutsky,¹ and Steven A. Thomas¹

¹Department of Pharmacology and Neuroscience Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6084, and ²Division of Neonatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104

Memories for emotionally arousing experiences are typically vivid and persistent. The recurrent, intrusive memories of traumatic events in post-traumatic stress disorder (PTSD) are an extreme example. Stress-responsive neurotransmitters released during emotional arousal are proposed to enhance the consolidation of fear memory. These transmitters may include norepinephrine and epinephrine (NE/E) because stimulating β -adrenergic receptors shortly after training can enhance memory consolidation. However, mice lacking NE/E acquire and consolidate fear memory normally. Here, we show by using pharmacologic and genetic manipulations in mice and rats that NE/E are not essential for classical fear memory consolidation because signaling by the β_2 -adrenergic receptor is redundant with signaling by dopamine at the D₅-dopaminergic receptor. The intracellular signaling that is stimulated by these receptors to promote consolidation uses distinct G proteins to redundantly activate phospholipase C. The results support recent evidence indicating that blocking β -adrenergic receptors alone shortly after trauma may not be sufficient to prevent PTSD.

Introduction

The basolateral nuclei of the amygdala (BLA) is a brain region critical to the consolidation of fear memory (Pape and Pare, 2010). Changes in neuromodulatory signaling in the BLA during emotional arousal are believed to underlie the powerful and persistent consolidation of long-term fear memory. Neuromodulators such as norepinephrine and epinephrine (NE/E) that are released during fearful or traumatic events can promote memory consolidation for such experiences. For example, stimulating β -adrenergic receptors by infusing NE or β -adrenergic selective agonists into the BLA shortly after instrumental fear conditioning enhances long-term memory (McGaugh and Roozendaal, 2002).

In contrast, a requirement for β -adrenergic signaling in fear memory consolidation is less clear. In one study, BLA infusion of β -adrenergic receptor antagonists impaired consolidation of instrumental fear (Gallagher et al., 1977). However, results from

other studies suggest that β signaling is not required for consolidation of instrumental fear (Izquierdo and Dias, 1983; Izquierdo et al., 1992). Negative results have also been reported for classical fear. Infusing a β -adrenergic receptor antagonist into the BLA shortly before or immediately after classical fear conditioning does not impair consolidation (Miserendino et al., 1990; Debiec and LeDoux, 2004). Furthermore, instrumental and classical fear memory consolidation are normal in mice completely lacking NE/E (Thomas and Palmiter, 1997; Murchison et al., 2004) or harboring a targeted disruption of either the β_1 - or β_2 -adrenergic receptor gene (Schutsky et al., 2011).

A potential resolution to the observation that the adrenergic system can influence, but is not required for, consolidation is that there is redundancy between the adrenergic system and another neurotransmitter system. In redundancy, the loss of a single system will have no effect on consolidation. However, interfering with two relevant but redundant systems simultaneously could have considerable effect. Classically, β -adrenergic receptors couple to G_s proteins that act to stimulate adenylyl cyclase (AC) and elevate intracellular levels of cAMP, a second messenger required in the BLA for fear memory consolidation (Schafe and LeDoux, 2000). It is through G_s and cAMP that β receptors are currently proposed to enhance synaptic plasticity and memory consolidation (Sara, 2009; Tully and Bolshakov, 2010).

For this study, we considered whether DA might serve as a stress-responsive system that acts in a redundant manner with NE/E in promoting consolidation. Like NE/E, extracellular levels of DA are elevated for minutes following fear conditioning (Inglis and Moghaddam, 1999; Anstrom and Woodward, 2005). Like β receptors, the D₁ class of DA receptors, consisting of the D₁ and D₅ receptors (D_{1,5}), can couple to the G_s class of G proteins and elevate cAMP (Sibley and Monsma, 1992), providing an oppor-

Received Oct. 17, 2011; revised Nov. 18, 2011; accepted Dec. 9, 2011.

Author contributions: M.O., M.B.Y., M.M.L. and S.A.T. designed research; M.O., M.B.Y., M.M.L. and K.S. performed research; M.O., M.B.Y., M.M.L., K.S. and S.A.T. analyzed data; and S.A.T. and M.B.Y. wrote the paper.

This work was supported by Department of Defense Grant PT075099 and NIH Grant 5R01MH063352 to S.A.T. We thank Dainippon Sumitomo Pharma (Osaka, Japan) for their generous gift of l-threo-3,4-dihydroxyphenylserine used to rescue *Dbh*^{−/−} mice prenatally, and B. Kobilka (Stanford University), M. Xu (University of Chicago), and D. Sibley (National Institutes of Health) for providing stock for the β receptor and DA receptor KO mouse lines.

The authors declare no conflict of interest.

Correspondence should be addressed to Dr. Steven Thomas, Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, 103 John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104-6084. E-mail: sathomas@upenn.edu.

M. M. Lestini's present address: Division of Neonatology, Department of Pediatrics, Hackensack University Medical Center, 30 Prospect Avenue, Hackensack, NJ 07601.

K. Schutsky's present address: Department of Microbiology and Immunology, Center for Neurovirology, 1020 Locust Street, Jefferson Alumni Hall, Room 465, Philadelphia, PA 19107.

DOI:10.1523/JNEUROSCI.5231-11.2012

Copyright © 2012 the authors 0270-6474/12/321932-10\$15.00/0

tunity for redundant signaling between these two classes of catecholamine receptors. Here, we use genetic and pharmacologic approaches in mice and rats to demonstrate that DA and NE/E have redundant roles in the BLA for the consolidation of classical fear memory. Surprisingly, we found that the signaling by these neuromodulators that is critical for consolidation converges on the activation of phospholipase C.

Materials and Methods

Animals. Wild-type, *Dbh*^{+/−}, *Dbh*^{−/−}, *Adrb1*^{−/−} (β_1 KO), *Adrb2*^{−/−} (β_2 KO), and *Drd1*^{−/−} (D₁ KO) mice were on a hybrid 129/Sv × C57BL/6 background, while *Drd5*^{−/−} (D₅ KO) mice were on a C57BL/6 background (Xu et al., 1994; Thomas et al., 1995; Rohrer et al., 1996; Chruscinski et al., 1999; Holmes et al., 2001). Mice were generated by mating either heterozygotes or homozygotes, and genotype was determined by PCR. The prenatal loss of *Dbh*^{−/−} mice was rescued as previously described (Ouyang et al., 2004). No significant differences were found by gender or parental genotype so data were combined. Female Fischer 344 rats (Harlan) were 3–4 weeks old upon arrival. Animals were maintained on *ad libitum* food and water and a 12 h light/dark cycle, with lights on beginning at 7:00 A.M. Animals were housed in small, quiet rooms for at least 3 weeks before studies began. Mice were 3–6 months old and rats were 8–11 weeks old when tested. Studies were performed during the light phase, with most experiments taking place between 9:00 A.M. and 5:00 P.M. Studies were in accordance with NIH guidelines and had the approval of the Institutional Animal Care and Use Committee at the University of Pennsylvania.

Classical fear conditioning. Adjacent to the training room, animals were placed in pairs (mice) or singly (rats) into opaque plastic holding buckets (12 cm diameter) with bedding and lids for 30–60 min before being manipulated further. Animals were given two 3 min preconditioning handling sessions over 2 d in the training room. Saline was injected at the end of handling each day. For conditioning, animals were placed in the training apparatus (ENV-010MC with ENV-414S, Med Associates) for 2 min, after which an 84 dB, 4.5 kHz tone was activated for 30 s. Two seconds before the end of the tone, a 2 s footshock was delivered (1 mA for mice, 1.7 mA for rats). The animal was removed from the apparatus and injected 30 s after shock, and then returned to its home cage. The apparatus was cleaned with Versa-Clean (Thermo Fisher Scientific) between subjects. Experiments examining enhancement of consolidation in mice were conducted identically except that a 0.4 mA footshock was used. Pseudoconditioning was similar to conditioning except that animals received the 2 s, 1 mA footshock immediately after being placed in the conditioning apparatus, while activation of the 30 s tone occurred at the normal time 2 min later. Contextual fear was tested for 5 min in the conditioning apparatus in the absence of the tone. Cued fear was tested in a Plexiglas cylinder (21 cm diameter, 24 cm tall) with green wire grid floor and vertical green and white wall stripes 240° around, and was cleaned with lemon-scented Ajax between subjects. After 2 min, the training tone was turned on for 3 min. Percentage freezing was estimated by scoring the presence or absence of nonrespiratory movement every 5 s. Tests were conducted 1 d after training.

Instrumental fear conditioning. Animals were handled as described above. Training consisted of placing an animal in the lighted chamber of the apparatus used for classical conditioning and timing its latency to fully enter (except for the tail) the dark chamber. Once the animal entered the dark chamber, the retractable partition separating the two chambers was lowered and a footshock was delivered for 2 s (0.35 mA). The animal was removed from the apparatus and injected 15 s after shock, and then returned to its home cage. Animals that did not enter the dark chamber after 100 s during conditioning were excluded (<4% of mice, independent of genotype). Testing was identical to training except that no shock was delivered and the partition remained up. Latencies to enter the dark chamber were recorded. If an animal did not enter the dark chamber within 10 min, it was returned to its cage and assigned a latency of 10 min. Tests were conducted 1 d after training.

Drugs. SCH 23390 HCl, ecopipam (SCH 39166 HBr), SKF 38393 HBr, SKF 83959 HBr, SKF 83822 HBr, (−)-propranolol HCl, CGP 20172A

HCl, ICI 118,551 HCl, procaterol HCl, pertussis toxin, edelfosine (all Tocris Bioscience) and m-3M3FBS (Sigma) were administered intraperitoneally or infused into the BLA immediately after training. The phospholipase C (PLC) inhibitor U73122 could not be used in these studies because its delivery requires high percentage organic vehicles that disrupt memory consolidation on their own. Xamoterol hemifumarate (Tocris Bioscience) was administered intraperitoneally 60 min before testing contextual fear in *Dbh*^{−/−} mice to rescue memory retrieval (Murchison et al., 2004). Drugs were dissolved in 0.9% saline (SKF compounds and procaterol also contained 0.1 mg/ml ascorbic acid, pH 7.4, Sigma). Vehicle was saline with or without 0.1 mg/ml ascorbic acid. Systemic injection volumes were 10 μ l/g body weight.

CNS infusion. Two guide cannulae mounted on a base plate (C315GS system, Plastics One) were implanted under pentobarbital anesthesia (72.5 mg/kg) using a stereotax (SAS75/EM40M, Cartesian Research). The guides were placed 1.25 mm posterior to bregma and 3.5 mm bilateral for BLA infusions. The guide and dummy cannulae projected 3 mm below the base plate. Habituation of the animals to the investigator and the infusion procedure began a couple of days later with a 3 min handling session followed by 3 min of immobilization (gently holding the nape of the neck and body) that mimicked infusion. Five handling sessions were given, with two of them being on the 2 d immediately preceding training and the final one being 1 h before training. Immediately after training, mice were infused bilaterally using injection cannulae that extended 2.8 mm below the tip of the guide cannulae. Infusion was 0.2 μ l/side at 0.08 μ l/min, with the injection cannulae being left in place for 30 s before the mouse was returned to its home cage. Because studies indicate that the effects of PTx are best evaluated 3 d after infusion, PTx was infused into the BLA 3 d before training (Goh and Pennefather, 1989; Stratton et al., 1989). For sites adjacent to the BLA, infusions were displaced 0.75 mm from the BLA coordinates in the direction indicated. As a result, dorsal was in the posterior striatum, ventral was near the ventral piriform cortex, medial was at the central/medial amygdala border, lateral was in the dorsal piriform cortex, rostral was in the extreme anterior amygdala, and caudal was in the extreme posterior amygdala.

IP₃ levels. Mice were anesthetized with CO₂, killed by cervical dislocation and brains were rapidly removed, frozen in isopentane on dry ice and stored at −80°C. Two frozen coronal sections (400 μ m) that contained the BLA were cut by cryostat (HM505E, Microm) from each mouse, and a 0.5 mm diameter punch of BLA tissue was collected bilaterally from each slice. The four punches per mouse were pooled and homogenized on ice with three 2 s pulses (5 s interval) in 125 μ l of 4% perchloric acid using a Sonic Dismembrator 100 set on level 3 (Thermo Fisher Scientific). After 15 min on ice, samples were stored overnight at −80°C. The next day samples were centrifuged at 4°C and 2000 \times g for 15 min, and the pellet was stored at −80°C for subsequent Bradford assay to determine total protein. Supernatants were neutralized on ice with 10 M KOH (to precipitate the perchloric acid) and centrifuged at 4°C and 2000 \times g for 15 min. Supernatant (100 μ l) was then used in the [³H]-IP₃ radioreceptor assay (PerkinElmer) according to instructions. Pilot experiments indicated that IP₃ levels were elevated 30 min after systemic agonist injection, but not at 15, 22, or 35 min.

Statistics. Data were analyzed with Statistica 9.1 (StatSoft) using one- or two-way ANOVA with $\alpha = 0.05$. The Bartlett Chi-square test was used to analyze homogeneity of variances. Post hoc comparisons were made using Duncan's range test. In Figures 1–9, data are presented as mean ± SE. Comparisons marked as significant are to the reference group except where indicated.

Results

Redundancy between D_{1/5}-dopaminergic and β_2 -adrenergic signaling

To determine whether signaling by DA might be redundant with that for NE/E, we first examined the effect of the D_{1,5} antagonist SCH 23390 (SCH) on memory consolidation when administered immediately after classical fear conditioning in wild-type mice and mice completely lacking NE/E (Iorio et al., 1983). Mice that lacked NE/E were homozygous for targeted disruption of the




Figure 1. $D_{1,5}$ -dopaminergic signaling is redundant with β_2 -adrenergic signaling for fear memory consolidation. **A**, General time line for fear memory experiments, indicating that drugs were administered immediately after conditioning and testing was performed the next day. More extensive pretraining handling was performed for CNS infusion experiments. For this figure, conditioning was with intense shock (1 mA). **B–E**, A $D_{1,5}$ receptor antagonist (SCH 23390 or ecopipam) was injected intraperitoneally. **B**, Cued fear test. $p = 0.0001$ for the main effect of dose; $p < 0.0001$ for the main effect of genotype; and $p = 0.0004$ for the interaction of dose and genotype (6/group). **C**, Contextual fear test. The β_1 -adrenergic receptor agonist xamoterol (3 mg/kg) was administered 60 min before testing contextual fear in $Dbh^{-/-}$ mice to rescue their contextual memory retrieval deficit (Murchison et al., 2004). $p = 0.027$ for the main effect of treatment; $p = 0.005$ for the main effect of genotype; and $p = 0.039$ for the interaction of treatment and genotype (6/group). **D**, Cued fear test. $p = 0.0006$ for the main effect of dose; $p < 0.0001$ for the main effect of genotype; and $p = 0.0003$ for the interaction of dose and genotype (5–8/group). **E**, Instrumental fear test. Main effects and their interaction were not significant (7–8/group). **F**, **G**, Cued fear test. The $D_{1,5}$ antagonist SCH 23390 (30 $\mu\text{g/kg}$) was administered to wild-type mice either in saline (– or 0) or in combination with a β -adrenergic receptor antagonist. **F**, The β antagonists used were either the nonselective β blocker (-)-propranolol (β), the β_1 -selective blocker CGP 20712A (β_1), or the β_2 -selective blocker ICI 118,551 (β_2), each at 1 mg/kg. $p = 0.0005$ for the main effect of treatment (6–9/group). **G**, ICI tested at lower doses in combination with SCH (30 $\mu\text{g/kg}$). $p = 0.003$ for the main effect of dose (6–12/group). **H**, SCH (30 $\mu\text{g/kg}$) was administered with the β_2 agonist procatenol. $p = 0.0008$ for the main effect of dose (6/group). * $p < 0.05$, ^ $p < 0.01$, # $p < 0.001$.

dopamine β -hydroxylase gene ($Dbh^{-/-}$) (Thomas et al., 1995). The same general treatment protocol was used for this and subsequent experiments (Fig. 1A). One day after fear conditioning, $Dbh^{-/-}$ mice treated immediately after training with the $D_{1,5}$ antagonist SCH at 10–30 $\mu\text{g/kg}$ body weight exhibited low freezing in response to the training cue (a tone that immediately preceded shock) compared with $Dbh^{-/-}$ mice treated with vehicle or with wild-type mice treated with either SCH or vehicle (Fig. 1B).

In a separate group of mice tested for their contextual fear of the training apparatus (no tone), SCH also impaired consolidation selectively in $Dbh^{-/-}$ mice relative to wild-type mice (Fig. 1C). Mice lacking NE/E exhibit impaired retrieval of contextual fear 1 d after conditioning due to lack of β_1 signaling (Murchison et al., 2004). Thus, to examine potential effects of NE/E deficiency on consolidation, retrieval was rescued in the contextual fear experiment by administering the β_1 -selective agonist xamoterol shortly before testing (Hicks et al., 1987; Murchison et al., 2004). For simplicity, subsequent experiments using classical fear conditioning focused on cued fear, for which retrieval is independent of NE/E.

In addition to classical fear, we examined whether consolidation of instrumental fear requires NE/E and/or $D_{1,5}$ signaling. Wild-type and $Dbh^{-/-}$ mice were treated with either vehicle or SCH immediately after conditioning. Neither the absence of NE/E by itself nor treatment of wild-type mice with SCH impaired consolidation of instrumental fear (Fig. 1D), confirming previous observations with $Dbh^{-/-}$ mice (Thomas and Palmiter, 1997). Furthermore, and in contrast to the results for classical fear, treatment of $Dbh^{-/-}$ mice with SCH also had no effect on the consolidation of instrumental fear. Differences in signaling mechanisms between instrumental and classical fear conditioning may parallel differences in their reliance on the amygdala (Wilensky et al., 2000).

A potential confound of the above results for classical fear conditioning is that SCH is also an agonist at serotonin 5-HT_{2C} receptors (Ramos et al., 2005). To further examine a role for $D_{1,5}$ receptors, we used a less potent but more selective $D_{1,5}$ antagonist, ecopipam, that lacks serotonin receptor activity (Chipkin et al., 1988). Similar to SCH, ecopipam impaired cued fear memory consolidation selectively in $Dbh^{-/-}$ mice (Fig. 1E).

The results to this point are consistent with two distinct potential roles for DA in classical fear memory consolidation. First, DA might not normally play a role in consolidation, but instead might compensate for the chronic lack of NE/E in $Dbh^{-/-}$ mice. Alternatively, NE/E and DA might both contribute to consolidation, but their roles would be redundant. In the latter case, stimulation of either system might facilitate consolidation, but only impairments in signaling by both systems would cause deficits in consolidation. To evaluate these possibilities, wild-type mice were treated with SCH, the β -adrenergic receptor antagonist propranolol, or the combination. Mice treated with SCH or propranolol alone exhibited normal cued fear memory, while mice treated with the combination of SCH plus propranolol exhibited impaired memory (Fig. 1F). Furthermore, a selective β_2 antagonist (ICI 118,551 = ICI) but not a selective β_1 antagonist (CGP 20712A) impaired consolidation when combined with SCH, while ICI alone had no effect (O'Donnell and Wanastall, 1980; Dooley et al., 1986). Dose-response data indicated that ICI was fully effective at 30 $\mu\text{g/kg}$ when it was combined with SCH (Fig. 1G). The results provide strong initial support for the idea that DA and NE/E act in a redundant manner to consolidate classical fear memory.

Results from the antagonist studies suggest that β_2 signaling is required for the role of NE/E in consolidation. To determine whether β_2 signaling is sufficient for the role of NE/E, $Dbh^{-/-}$ mice were treated with both SCH (to impair consolidation) and various doses of the selective β_2 agonist procatenol (Waelbroeck




Figure 2. Redundancy for fear memory consolidation also occurs in rats. Experimental design was as depicted in Figure 1*A* using intense shock (1.7 mA for rats). Rats were treated with either saline (0), SCH, ICI or the combination. $p < 0.0001$ for the main effect of treatment (4–8/group). * $p < 0.001$.

et al., 1983). Procaterol provided a dose-dependent rescue of cued fear memory consolidation, suggesting that β_2 signaling is sufficient for mediating the role of NE/E in consolidation in the absence of $D_{1/5}$ signaling (Fig. 1*H*).

Redundancy also occurs in rats, is localized to the BLA, and is mediated by D_5 receptors

Many prior studies examining the roles of catecholamines in fear memory have used rats rather than mice. To determine whether redundancy between catecholamines generalizes across species, rats were fear conditioned and treated with SCH and/or ICI. Consistent with the results obtained from mice, only concurrent administration of SCH and ICI impaired cued fear memory consolidation in rats (Fig. 2).

Because the BLA is critical for fear memory consolidation, we asked whether redundant catecholamine signaling occurs in this brain region. One week before conditioning, mice were cannulated to permit infusions into the BLA. When SCH and/or ICI were infused bilaterally immediately after training, only the combination of drugs impaired memory consolidation (Fig. 3*A*). To determine whether drug infusions into the BLA impair consolidation by affecting adjacent brain regions instead of the BLA, the SCH/ICI combination was infused into each of six locations surrounding the BLA (Fig. 3*C*). These infusions did not impair consolidation, indicating that the BLA is the site of drug action (Fig. 3*B*).

To genetically test a role for β receptors, mice with a targeted disruption of the gene for either the β_1 - or β_2 -adrenergic receptor were treated with SCH or vehicle. While SCH had no effect on consolidation in β_1 knock-out (KO) mice (Fig. 4*A*), SCH impaired consolidation in β_2 KO mice (Fig. 4*B*). As a genetic complement to nonselective β receptor blockade, cued fear memory was also examined in $\beta_{1,2}$ double KO mice, and no deficit was observed (Fig. 4*C*). Importantly, the pharmacologic studies to this point were unable to distinguish between the potential roles of D_1 and D_5 receptors in consolidation due to a lack of receptor subtype selectivity of the drugs. For this purpose, gene-targeted mice were used. While the β_2 antagonist ICI had no effect on consolidation in D_1 KO mice (Fig. 4*D*), ICI impaired consolidation in D_5 KO mice (Fig. 4*E*), indicating that the role of DA in consolidation is mediated by the D_5 receptor.

Agonists of β_2 or D_5 receptors enhance fear memory consolidation

Given the roles for β_2 and D_5 receptors defined above, we asked whether activating these specific receptors shortly after conditioning would enhance fear memory consolidation in mice when

trained with a lower shock intensity. For NE/E, enhancement of consolidation by β receptor stimulation has not been demonstrated for classical fear, although this has been demonstrated for instrumental fear (McGaugh and Roozendaal, 2002). For DA, results from BLA infusion of a $D_{1,5}$ receptor agonist before classical fear conditioning suggest that stimulation of these receptors enhances either acquisition or consolidation (Guarraci et al., 1999).

When wild-type mice were systemically injected with the β_2 agonist procaterol immediately after conditioning, cued fear memory was significantly enhanced (Fig. 5*A*). When mice were injected with the $D_{1,5}$ agonist SKF 38393 immediately after conditioning, cued fear memory was also significantly enhanced (Fig. 5*B*). Of note, $D_{1,5}$ receptors can activate various downstream effectors, including AC and PLC, and certain $D_{1,5}$ agonists can induce the selective activation of either AC or PLC (Undie et al., 1994; Jin et al., 2003). To gain insight into the initial mechanism by which $D_{1,5}$ receptors might enhance consolidation, effector-selective $D_{1,5}$ agonists were used. While an AC-selective $D_{1,5}$ agonist did not significantly alter consolidation, a PLC-selective $D_{1,5}$ agonist enhanced consolidation to an extent similar to that for the nonselective $D_{1,5}$ agonist used initially (Fig. 5*B–D*). Because $D_{1,5}$ agonists do not distinguish between these two receptors, receptor KO and wild-type littermate control mice were used. The ability of the nonselective and PLC-selective $D_{1,5}$ agonists to enhance consolidation was absent in D_5 KO mice, although the β_2 agonist procaterol remained effective (Fig. 5*E*). Similarly, the ability of procaterol to enhance consolidation was absent in β_2 KO mice, although a $D_{1,5}$ agonist remained effective (Fig. 5*F*).

β_2 and D_5 signaling in consolidation converge on the activation of PLC

Given that D_5 may activate PLC to enhance fear memory consolidation, we asked whether directly stimulating PLC activity with the agonist m-3M3FBS enhances consolidation (Bae et al., 2003). In support of a role for PLC, infusion into the BLA of this PLC agonist also enhanced consolidation (Fig. 6*A*). We next asked whether inhibiting PLC activity would impair consolidation by infusing the PLC inhibitor edelfosine into the BLA immediately after training (Powis et al., 1992). Edelfosine dose-dependently impaired consolidation (Fig. 6*B*), suggesting that activation of PLC may be required for fear memory consolidation, and that this could be a site of convergence for D_5 and β_2 signaling. Infusion of edelfosine either 1 d before or 4 h after conditioning had no effect on cued fear memory, indicating that edelfosine does not lesion the BLA or impair expression (Fig. 6*C*). Although prior studies support the possibility that D_5 may signal via G_q and PLC in the amygdala (Friedman et al., 1997; Leonard et al., 2003; Sahu et al., 2009), the only data indicating that β_2 could signal via PLC come from heterologous expression of β_2 receptors in HEK-293 cells *in vitro* (Keiper et al., 2004).

To determine whether D_5 , β_2 , or both receptors might signal via PLC to promote consolidation, we used edelfosine in two complementary experiments. The first experiment was based on the idea that PLC activity could be reduced to a point where it becomes rate-limiting for consolidation. To achieve this, edelfosine was infused into the BLA at the highest dose (0.2 ng) that did not impair consolidation. We then examined the combinatorial effects of PLC and receptor blockade. Edelfosine at 0.2 ng was administered with a dose (50 ng) of either SCH or ICI that impairs consolidation when combined with each other but not when given alone (Fig. 3*A*). The combination of edelfosine plus




Figure 3. BLA is the locus of redundant signaling in fear memory consolidation. Experimental design was as depicted in Figure 1*A* using intense shock (1 mA for mice). *A*, Drugs were infused bilaterally into the BLA of wild-type mice. $p < 0.0001$ for the main effect of treatment (5–8/group). *B*, The combination of SCH plus ICI (each 50 ng) was infused bilaterally into the BLA or into adjacent brain regions displaced 0.75 mm in the direction indicated. $p < 0.0001$ for the main effect of treatment (5–6/group). *C*, Injection cannula tips were located within spheres marked by the circles on the atlas drawings (Frankland and Paxinos, 1997). * $p < 0.001$.




Figure 4. The role of DA in fear memory consolidation is mediated by D_5 receptors. Experimental design was as depicted in Figure 1*A* using intense shock (1 mA). *A*, *B*, Either saline (Sal) or a $D_{1/5}$ antagonist (SCH, 30 μ g/kg) was administered to wild-type (WT) and β receptor knock-out (KO) mice. For β_2 mice, $p = 0.016$ for the main effect of treatment; $p = 0.0044$ for the main effect of genotype; and $p = 0.0006$ for the interaction of treatment and genotype (5/group). *C*, Sal was administered to WT and $\beta_{1,2}$ double KO mice. No significant difference was observed (5/group). *D*, *E*, Either Sal or a β_2 antagonist (ICI, 30 μ g/kg) was administered to WT and DA receptor KO mice. For D_5 mice, $p = 0.004$ for the main effect of treatment; $p = 0.0006$ for the main effect of genotype; and $p = 0.029$ for the interaction of treatment and genotype (5–8/group). * $p < 0.001$.

SCH and the combination of edelfosine plus ICI each impaired consolidation (Fig. 6*B*).

The second experiment examined the ability of agonists to enhance consolidation when PLC was inhibited. Edelfosine, at the smallest dose (2 ng) that impaired consolidation of high-shock intensity training, was infused into the BLA while administering a $D_{1,5}$ or β_2 agonist systemically immediately after training with lower shock intensity. Edelfosine blocked the enhancements of consolidation induced by the $D_{1,5}$ agonist and by the β_2 agonist (Fig. 6*D*).

Results from the above two experiments suggested that D_5 and β_2 receptors may both signal via PLC to promote consolidation. To further test this possibility, inositol-1,4,5-trisphosphate (IP_3), a second messenger molecule generated by PLC activity, was measured in the BLA following systemic administration of a $D_{1,5}$ or β_2 agonist. Significant increases in IP_3 levels in the BLA were observed *ex vivo* with each agonist in wild-type mice (Fig. 7*A*).

Because this is a novel finding for β_2 stimulation, β_2 KO mice were also examined. In these mice, a $D_{1,5}$ agonist but not a β_2 agonist caused BLA IP_3 levels to increase (Fig. 7*B*). For D_5 , others have shown that the ability of $D_{1,5}$ agonists to augment IP_3 levels in various brain regions is absent in D_5 KO mice (Sahu et al., 2009).

Finally, we asked whether learning-specific activation of PLC occurs in the BLA by measuring IP_3 levels *ex vivo* following fear conditioning. IP_3 levels were elevated in the BLA 30 min after fear conditioning when compared with pseudoconditioning or no conditioning (Fig. 7*C*). The elevation in IP_3 was selective for this time point, as several earlier and later time points from 3–60 min did not show elevation (Fig. 7*D*). Systemic administration of SCH or ICI immediately after conditioning had no effect on IP_3 levels 30 min after conditioning (Fig. 7*E*). In contrast, administration of SCH and ICI combined significantly reduced IP_3 levels relative to vehicle administration, demon-




Figure 5. Agonists of β_2 or D_5 receptors enhance fear memory consolidation. Experimental design was as depicted in Figure 1A using moderate shock (0.4 mA). **A**, Various doses of the β_2 agonist procaterol were injected immediately after conditioning. $p = 0.043$ for the main effect of dose (6–11/group). **B–D**, Various doses of either a nonselective $D_{1,5}$ agonist (SKF 38393), a $D_{1,5}$ agonist that selectively activates AC (SKF 83822), or a $D_{1,5}$ agonist that selectively activates PLC (SKF 83959) were tested. $p = 0.017$ and $p = 0.0038$ for the main effect of dose for SKF 38393 and SKF 83959, respectively (8–13/group). **E, F**, Procaterol (50 $\mu\text{g/kg}$) or $D_{1,5}$ agonist (5 mg/kg for SKF 38393 or 2 mg/kg for SKF 83959) was administered to β_2 KO and D_5 KO mice and their wild-type littermate controls. **E**, $p = 0.0001$ for the main effect of treatment; $p = 0.013$ for the main effect of genotype; and $p = 0.015$ for the interaction of treatment and genotype (8–31/group). **F**, $p < 0.0001$ for the main effect of treatment; $p = 0.0009$ for the main effect of genotype; and $p = 0.009$ for the interaction of treatment and genotype (5–13/group). * $p < 0.05$, ^ $p < 0.01$, # $p < 0.001$.




Figure 6. PLC is a critical regulator of consolidation. Experimental design was similar to that depicted in Figure 1A using moderate or intense shock (0.4 or 1 mA). **A**, The PLC agonist m-3M3FBS was infused into the BLA of wild-type mice after training with 0.4 mA. $p = 0.001$ for the main effect of dose (5/group). **B**, The PLC inhibitor edelfosine alone or in combination with either ICI (50 ng) or SCH (50 ng) was infused into the BLA after training with 1 mA. $p < 0.0001$ for the main effect of treatment (5–7/group). **C**, Infusion time is relative to conditioning. Cued fear testing was performed 1 d after training. The main effects of treatment and of time, as well as their interaction, were not significant (5/group). **D**, Mice were fear conditioned using 0.4 mA. Saline (Sal) or edelfosine (2 ng) was then infused into the BLA, and immediately afterward either vehicle, SKF 83959 (2 mg/kg) or procaterol (50 ng/kg) was injected intraperitoneally. $p = 0.001$ for the main effect of agonist; $p < 0.0001$ for the main effect of antagonist; and $p = 0.0027$ for the interaction of agonist and antagonist (5/group). * $p < 0.05$, ^ $p < 0.01$, # $p < 0.001$.




Figure 7. Redundancy between β_2 and D_5 signaling occurs via activation of PLC. Experimental design was similar to that depicted in Figure 1A using moderate or intense shock (0.4 or 1 mA). **A**, Wild-type mice were injected intraperitoneally with either vehicle, SKF 83959 (2 mg/kg) or procaterol (50 ng/kg) and killed 30 min later. Punches from the BLA were assayed for IP₃ (pmol/mg protein). $p = 0.045$ for the main effect of agonist (10/group). **B**, β_2 KO mice were treated as described in **A**. $p = 0.044$ for the main effect of agonist (9–10/group). **C**, Mice were treated as indicated and killed 30 min later. Shock intensity was 1 mA for the pseudo- and classical-conditioned groups. The classical-conditioned group exhibited significantly higher IP₃ levels in the BLA relative to the pseudo-conditioned ($p = 0.033$) and naive ($p = 0.016$) groups. $p = 0.021$ for the main effect of conditioning (6–10/group). **D**, Mice were handled as in **C** and killed at the times indicated. Main effects and their interaction were not significant (5–7/group). **E**, Mice were fear conditioned using 1 mA and then injected intraperitoneally with either Sal, SCH (30 $\mu\text{g/kg}$), ICI (30 $\mu\text{g/kg}$), or the combination of SCH and ICI, and killed 30 min later. Only combined treatment caused a significant reduction in conditioning-induced IP₃ levels in the BLA. $p = 0.039$ for the main effect of treatment (21/group). * $p < 0.05$.

ing that redundancy in receptor function extends to the learning-induced production of IP₃ in the BLA.

β_2 activation of PLC in the BLA is mediated by G_{i/o}

While there is considerable evidence indicating that D₅ couples to G_q to activate PLC, evidence for the coupling of β_2 to G_q is lacking. A study in HEK-293 cells suggested that by coupling to G_s, β_2 receptors can sequentially activate AC, Epac, Rap2, and PLC ϵ . However, recent results from our laboratory suggested an alternate potential mechanism for coupling β_2 to PLC in the brain. Retrieval of contextual fear memory requires NE, β_1 , G_s, and AC signaling in the hippocampus (Ouyang et al., 2008). β_2 signaling impairs retrieval by stimulating the inhibitory G_i class of G proteins, causing cAMP levels to decrease in the hippocampus (Schutsky et al., 2011). Of potential relevance, G_i signaling can also result in the activation of PLC by releasing $\beta\gamma$ subunits that are capable of stimulating PLC β isoforms. Therefore, we asked whether such a mechanism might apply to β_2 signaling in the BLA for consolidation.

Pertussis toxin (PTx) inactivates G_{i/o} proteins through ADP ribosylation, uncoupling them from their receptors. Because it takes several days to observe optimal efficacy when PTx is administered *in vivo*, PTx was infused into the BLA 3 d before conditioning (Goh and Pennefather, 1989; Stratton et al., 1989). BLA pretreatment with PTx had no effect on consolidation when saline was infused immediately after training, suggesting that G_{i/o} signaling is not essential for consolidation (Fig. 8A). That outcome was expected if only one of the redundant pathways uses G_{i/o}. Interestingly, pretreatment with PTx impaired consolidation when SCH was infused immediately after training. This outcome suggested that PTx pretreatment might be mimicking β_2 blockade. In support of this idea, pretreatment with PTx did not affect consolidation when ICI was infused immediately after training. Together, these results suggest that β_2 but not D₅ signaling in the BLA is mediated by G_{i/o}. To further test this possibility, PTx was infused into the BLA before treating with receptor agonists to enhance consolidation. PTx pretreatment blocked the enhancement of consolidation normally observed following systemic treatment with a β_2 agonist, but had no effect on the ability of a D_{1,5} agonist to enhance consolidation (Fig. 8B).

Discussion

In summary, our experiments identify an important but redundant role in classical fear memory consolidation for adrenergic signaling by β_2 receptors and dopaminergic signaling by D₅ receptors (Fig. 9). It is well recognized that there are multiple stress-response mediators with distinct but overlapping temporal and




Figure 8. β_2 activation of PLC in the BLA is mediated by G_{i/o}. Experimental design was similar to that depicted in Figure 1A using moderate or intense shock (0.4 or 1 mA). **A**, Pertussis toxin (PTx, 1 ng) or Sal was infused into the BLA 3 d before training. Immediately after training with 1 mA, either Sal, SCH (50 ng), or ICI (50 ng) was infused into the BLA. $p = 0.0002$ for the main effect of pretreatment; $p < 0.0001$ for the main effect of treatment; and $p < 0.0001$ for the interaction of pretreatment and treatment (5/group). **B**, Sal or PTx (1 ng) was infused into the BLA 3 d before training. Immediately after training with 1 mA, either Veh, SKF 83959 (2 mg/kg), or proctenol (50 μ g/kg) was injected intraperitoneally. $p = 0.018$ for the main effect of pretreatment; $p = 0.0009$ for the main effect of treatment; and $p = 0.014$ for the interaction of pretreatment and treatment (5–10/group). * $p < 0.05$; ^ $p < 0.01$; # $p < 0.001$.




Figure 9. Schematic diagram of functional redundancy. DA and NE are functionally redundant for fear memory consolidation in the BLA due to activation of PLC by D₅-G_q α and β_2 -G_{i/o} $\beta\gamma$ receptor signaling. Whether downstream signaling activated by the second messengers IP₃/Ca²⁺, diacylglycerol (DAG), or both is required is currently unclear, but both are likely required for activating a conventional isozyme of protein kinase C that is implicated in fear memory consolidation (Weeber et al., 2000). The cell type(s) in which this signaling occurs has yet to be defined. Phosphatidylinositol 4,5-bisphosphate (PIP₂) is a substrate of PLC. The endoplasmic reticulum (ER) stores Ca²⁺ for cytosolic release that is induced by IP₃.

mechanistic attributes (Joëls and Baram, 2009). Redundancy in systems responsible for potentially life-preserving processes such as long-term fear memory consolidation could be advantageous for survival. While we have found that NE and DA act in a redundant manner to consolidate classical fear memory, it is also possible that each has additional unique roles during (but not essential to) consolidation that may be identified in future studies.

While it has been widely hypothesized that endogenous NE/E and β -adrenergic signaling play critical roles in amygdala-dependent emotional memory consolidation, there is a paucity of evidence indicating that such signaling is uniquely required for this. In one study suggesting a unique role, various β receptor antagonists (including ICI) were infused into the BLA of rats immediately after cued fear conditioning, and impairment of cued fear was reported 1 d later (Qu et al., 2008). However, the doses of antagonist used were 100-fold higher than those found to be effective for ICI (when combined with SCH) in the current

study, and are considerably higher than what should be necessary for the size difference between rats and mice. Another study suggested that β receptors contribute to the acquisition but not consolidation of cued fear memory (Bush et al., 2010). However, it is difficult to reconcile the above observations with results from mouse genetic models, which do not support a unique role for β receptors in the acquisition, consolidation, or retrieval of cued fear memory: $Dbh^{-/-}$, β_1 KO, β_2 KO, or β_1/β_2 double KO mice do not exhibit cued fear deficits. Furthermore, our pharmacologic data from the current study and a previous study using mice and rats support the genetic findings (Murchison et al., 2004).

With respect to the role for DA, results from some studies suggest that $D_{1,5}$ signaling might be required for fear memory acquisition or consolidation (Guarraci et al., 1999; Greba and Kokkinidis, 2000). However, doses of SCH used in those studies (systemic or intra-BLA) were 10- to 100-fold higher than those found to be effective here, potentially lacking specificity for $D_{1,5}$ signaling. Relevant to this, we did not observe a fear conditioning deficit in D_1 or D_5 KO mice, confirming previous results (El-Ghundi et al., 1999; Holmes et al., 2001). These and our results contrast with a recent study reporting a deficit in either the acquisition or consolidation of fear-potentiated startle in D_1 KO mice (Fadok et al., 2009). In that study, conditioning used 30 trials reinforced by mild footshocks (0.2 mA for 0.5 s), while the current study examined the consolidation of more intense fear resulting from a single, strongly aversive footshock (1 mA for 2 s). It is possible that the mechanisms underlying the consolidation of multiple weakly reinforced training trials are different from those for a single, strongly reinforced event.

Given that β_2 and D_5 receptors can couple to G_s , and that cAMP signaling is required for classical fear memory consolidation (Schafe and LeDoux, 2000), it is interesting that neither β_2 nor D_5 signaling in the amygdala may increase cAMP levels. DA and $D_{1,5}$ agonists fail to elevate cAMP in the BLA (Leonard et al., 2003), and stimulation of β_2 receptors in hippocampal slices causes a decrease in cAMP (Schutsky et al., 2011). However, our results are consistent with observations indicating that $D_{1,5}$ agonists activate PLC rather than AC in the BLA, and that activation of PLC by DA is greatly diminished in D_5 but not D_1 KO mice (Friedman et al., 1997; Leonard et al., 2003; Sahu et al., 2009). Our results are also consistent with observations indicating that signaling by β_2 receptors in the heart and hippocampus depends predominantly on $G_{i/o}$ rather than G_s (Rockman et al., 2002; Schutsky et al., 2011).

Results from the current study indicate that β_2 and D_5 receptor signaling converge and become redundant by activating PLC. Remarkably, there is little evidence that canonical neurotransmitter signaling pathways that activate G_q/PLC are required for fear memory. Gene-targeted mice lacking expression of either metabotropic glutamate receptor mGluR1 or mGluR5, muscarinic acetylcholine receptor M₁ or M₃, serotonergic receptor 5-HT_{2a} or 5-HT_{2c}, adrenergic receptor α_{1d} , or histaminergic receptor H₁ all exhibit intact cued fear memory (Aiba et al., 1994; Lu et al., 1997; Tecott et al., 1998; Anagnostaras et al., 2003; Sadalge et al., 2003; Weisstaub et al., 2006; Dai et al., 2007; Poulin et al., 2010). Pharmacologically, there is evidence for and against mGluR5 signaling being required for cued fear memory (Nielsen et al., 1997; Rodrigues et al., 2002; Gravius et al., 2006), although stimulating mGluR1/5 receptors can enhance fear memory (Rudy and Matus-Amat, 2009). For NE/E, antagonist treatment suggests that α_1 -adrenergic signaling is not required for fear memory (Lazzaro et al., 2010). On the other hand, mice with a targeted disruption of the gene for PLC- β 1 exhibit greatly re-

duced contextual fear, although this could be due to a deficit in hippocampus-dependent memory rather than BLA-dependent fear memory per se (McOmish et al., 2008a,b).

Stimulation of PLC is likely to activate Ca^{2+} - and diacylglycerol-dependent signaling such as that mediated by protein kinase C (PKC) and calmodulin-dependent kinases (CaMKs). Genetic and pharmacologic data support a role for these kinases in fear memory. Genetic disruption of the PKC β gene or the CaMKIV gene results in impaired cued and contextual fear (Weeber et al., 2000; Wei et al., 2002), and inhibitors of PKC infused into the BLA shortly after conditioning impairs consolidation of instrumental fear (Bonini et al., 2005). In addition to the generation of IP₃, it will be valuable in future studies to identify the signaling events that are altered when β_2 and D_5 receptors are antagonized. It will also be valuable to determine in what cell type(s) these receptors act to promote consolidation, given that the potential expression and physiological effects of these receptors in the BLA are broad and diverse (Ciliax et al., 2000; Qu et al., 2008; Farb et al., 2010).

In humans, some studies indicate that blocking β receptors eliminates enhanced memory for emotionally arousing items, although other studies have not corroborated these findings (Cahill et al., 1994; O'Carroll et al., 1999). If β blockers have this effect, it would suggest a lack of redundancy under these conditions. This could be due to differences in arousal systems engaged by viewing aversive material versus experiencing a potentially life-threatening event, such as may occur with fear conditioning or events that can lead to the development of PTSD. Results from recent clinical trials suggest that β blockers are of limited efficacy in the prevention of PTSD (Stein et al., 2007; McGhee et al., 2009; Nugent et al., 2010). Our results suggest that combined D_5/β_2 blockade might be more efficacious.

References

- Aiba A, Chen C, Herrup K, Rosenmund C, Stevens CF, Tonegawa S (1994) Reduced hippocampal long-term potentiation and context-specific deficit in associative learning in mGluR1 mutant mice. *Cell* 79:365–375.
- Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. *Nat Neurosci* 6:51–58.
- Anstrom KK, Woodward DJ (2005) Restraint increases dopaminergic burst firing in awake rats. *Neuropharmacology* 30:1832–1840.
- Bae YS, Lee TG, Park JC, Hur JH, Kim Y, Heo K, Kwak JY, Suh PG, Ryu SH (2003) Identification of a compound that directly stimulates phospholipase C activity. *Mol Pharmacol* 63:1043–1050.
- Bonini JS, Cammarota M, Kerr DS, Bevilacqua LR, Izquierdo I (2005) Inhibition of PKC in basolateral amygdala and posterior parietal cortex impairs consolidation of inhibitory avoidance memory. *Pharmacol Biochem Behav* 80:63–67.
- Bush DE, Caparosa EM, Gekker A, LeDoux J (2010) Beta-adrenergic receptors in the lateral nucleus of the amygdala contribute to the acquisition but not the consolidation of auditory fear conditioning. *Front Behav Neurosci* 4:154.
- Cahill L, Prins B, Weber M, McGaugh JL (1994) Beta-adrenergic activation and memory for emotional events. *Nature* 371:702–704.
- Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH39166: a dopamine D1 selective benzodiazepine with potential antipsychotic activity. *J Pharmacol Exp Ther* 247:1093–1102.
- Chruscinski AJ, Rohrer DK, Schauble E, Desai KH, Bernstein D, Kobilka BK (1999) Targeted disruption of the beta2 adrenergic receptor gene. *J Biol Chem* 274:16694–16700.
- Ciliax BJ, Nash N, Heilman C, Sunahara R, Hartney A, Tiberi M, Rye DB, Caron MG, Niznik HB, Levey AI (2000) Dopamine D(5) receptor immunolocalization in rat and monkey brain. *Synapse* 37:125–145.
- Dai H, Kaneko K, Kato H, Fujii S, Jing Y, Xu A, Sakurai E, Kato M, Okamura N, Kuramasu A, Yanai K (2007) Selective cognitive dysfunction in mice lacking histamine H1 and H2 receptors. *Neurosci Res* 57:306–313.

Debiec J, LeDoux JE (2004) Disruption of reconsolidation but not consolidation of auditory fear conditioning by noradrenergic blockade in the amygdala. *Neuroscience* 129:267–272.

Dooley DJ, Bittiger H, Reymann NC (1986) CGP 20712 A: a useful tool for quantitating beta 1- and beta 2- adrenoceptors. *Eur J Pharmacol* 130: 137–139.

El-Ghundi M, Fletcher PJ, Drago J, Sibley DR, O'Dowd BF, George SR (1999) Spatial learning deficit in dopamine D(1) receptor knockout mice. *Eur J Pharmacol* 383:95–106.

Fadok JP, Dickerson TM, Palmiter RD (2009) Dopamine is necessary for cue-dependent fear conditioning. *J Neurosci* 29:11089–11097.

Farb CR, Chang W, LeDoux JE (2010) Ultrastructural characterization of noradrenergic axons and Beta-adrenergic receptors in the lateral nucleus of the amygdala. *Front Behav Neurosci* 4:162.

Frankland KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. San Diego: Academic.

Friedman E, Jin LQ, Cai GP, Hollon TR, Drago J, Sibley DR, Wang HY (1997) D1-like dopaminergic activation of phosphoinositide hydrolysis is independent of D1A dopamine receptors: evidence from D1A knockout mice. *Mol Pharmacol* 51:6–11.

Gallagher M, Kapp BS, Musty RE, Driscoll PA (1977) Memory formation: evidence for a specific neurochemical system in the amygdala. *Science* 198:423–425.

Goh JW, Pennefather PS (1989) A pertussis toxin-sensitive G protein in hippocampal long-term potentiation. *Science* 244:980–983.

Gravius A, Barberi C, Schäfer D, Schmidt WJ, Danysz W (2006) The role of group I metabotropic glutamate receptors in acquisition and expression of contextual and auditory fear conditioning in rats - a comparison. *Neuropharmacology* 51:1146–1155.

Greba Q, Kokkinidis L (2000) Peripheral and intraamygdalar administration of the dopamine D1 receptor antagonist SCH 23390 blocks fear-potentiated startle but not shock reactivity or the shock sensitization of acoustic startle. *Behav Neurosci* 114:262–272.

Guarraci FA, Frohardt RJ, Kapp BS (1999) Amygdaloid D1 dopamine receptor involvement in Pavlovian fear conditioning. *Brain Res* 827:28–40.

Hicks PE, Caverio I, Manoury P, Lefevre-Borg F, Langer SZ (1987) Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol. *J Pharmacol Exp Ther* 242:1025–1034.

Holmes A, Hollon TR, Gleason TC, Liu Z, Dreiling J, Sibley DR, Crawley JN (2001) Behavioral characterization of dopamine D5 receptor null mutant mice. *Behav Neurosci* 115:1129–1144.

Inglis FM, Moghaddam B (1999) Dopaminergic innervation of the amygdala is highly responsive to stress. *J Neurochem* 72:1088–1094.

Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. *J Pharmacol Exp Ther* 226:462–468.

Izquierdo I, Dias RD (1983) The influence of adrenergic receptor antagonists on the amnestic and anti-amnestic actions of adrenaline and tyramine. *Psychopharmacology* 80:181–183.

Izquierdo I, da Cunha C, Rosat R, Jerusalinsky D, Ferreira MB, Medina JH (1992) Neurotransmitter receptors involved in post-training memory processing by the amygdala, medial septum, and hippocampus of the rat. *Behav Neural Biol* 58:16–26.

Jin LQ, Goswami S, Cai G, Zhen X, Friedman E (2003) SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. *J Neurochem* 85:378–386.

Joëls M, Baram TZ (2009) The neuro-symphony of stress. *Nat Rev Neurosci* 10:459–466.

Keiper M, Stope MB, Szatkowski D, Böhm A, Tysack K, Vom Dorp F, Saur O, Oude Weernink PA, Evellin S, Jakobs KH, Schmidt M (2004) Epac- and Ca²⁺-controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors. *J Biol Chem* 279:46497–46508.

Lazzaro SC, Hou M, Cunha C, LeDoux JE, Cain CK (2010) Antagonism of lateral amygdala alpha1-adrenergic receptors facilitates fear conditioning and long-term potentiation. *Learn Mem* 17:489–493.

Leonard SK, Anderson CM, Lachowicz JE, Schulz DW, Kilts CD, Mailman RB (2003) Amygdaloid D1 receptors are not linked to stimulation of adenylate cyclase. *Synapse* 50:320–333.

Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM, Roder JC (1997) Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. *J Neurosci* 17:5196–5205.

McGaugh JL, Roozendaal B (2002) Role of adrenal stress hormones in forming lasting memories in the brain. *Curr Opin Neurobiol* 12:205–210.

McGhee LL, Maani CV, Garza TH, Desocio PA, Gaylord KM, Black IH (2009) The effect of propranolol on posttraumatic stress disorder in burned service members. *J Burn Care Res* 30:92–97.

McOmish CE, Burrows EL, Howard M, Hannan AJ (2008a) PLC-beta1 knockout mice as a model of disrupted cortical development and plasticity: behavioral endophenotypes and dysregulation of RGS4 gene expression. *Hippocampus* 18:824–834.

McOmish CE, Burrows E, Howard M, Scarr E, Kim D, Shin HS, Dean B, van den Buuse M, Hannan AJ (2008b) Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. *Mol Psychiatry* 13:661–672.

Miserendino MJ, Sananes CB, Melia KR, Davis M (1990) Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. *Nature* 345:716–718.

Murchison CF, Zhang XY, Zhang WP, Ouyang M, Lee A, Thomas SA (2004) A distinct role for norepinephrine in memory retrieval. *Cell* 117:131–143.

Nielsen KS, Macphail EM, Riedel G (1997) Class I mGlu receptor antagonist 1-aminoindan-1,5-dicarboxylic acid blocks contextual but not cue conditioning in rats. *Eur J Pharmacol* 326:105–108.

Nugent NR, Christopher NC, Crow JP, Browne L, Ostrowski S, Delahanty DL (2010) The efficacy of early propranolol administration at reducing PTSD symptoms in pediatric injury patients: a pilot study. *J Trauma Stress* 23:282–287.

O'Carroll RE, Drysdale E, Cahill L, Shahajan P, Ebmeier KP (1999) Memory for emotional material: a comparison of central versus peripheral beta blockade. *J Psychopharmacol* 13:32–39.

O'Donnell SR, Wanstall JC (1980) Evidence that ICI 118, 551 is a potent, highly Beta 2-selective adrenoceptor antagonist and can be used to characterize Beta-adrenoceptor populations in tissues. *Life Sci* 27:671–677.

Ouyang M, Hellman K, Abel T, Thomas SA (2004) Adrenergic signaling plays a critical role in the maintenance of waking and in the regulation of REM sleep. *J Neurophysiol* 92:2071–2082.

Ouyang M, Zhang L, Zhu JJ, Schwede F, Thomas SA (2008) Epac signaling is required for hippocampus-dependent memory retrieval. *Proc Natl Acad Sci* 105:11993–11997.

Pape HC, Pare D (2010) Plastic synaptic networks of the amygdala for the acquisition, expression, and extinction of conditioned fear. *Physiol Rev* 90:419–463.

Poulin B, Butcher A, McWilliams P, Bourgognon JM, Pawlak R, Kong KC, Bottrill A, Mistry S, Wess J, Rosethorne EM, Charlton SJ, Tobin AB (2010) The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. *Proc Natl Acad Sci* 107:9440–9445.

Powis G, Seewald MJ, Gratas C, Melder D, Riebow J, Modest EJ (1992) Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. *Cancer Res* 52:2835–2840.

Qu LL, Guo NN, Li BM (2008) Beta1- and beta2-adrenoceptors in basolateral nucleus of amygdala and their roles in consolidation of fear memory in rats. *Hippocampus* 18:1131–1139.

Ramos M, Goñi-Allo B, Aguirre N (2005) Administration of SCH 23390 into the medial prefrontal cortex blocks the expression of MDMA-induced behavioral sensitization in rats: an effect mediated by 5-HT2C receptor stimulation and not by D1 receptor blockade. *Neuropharmacology* 30:2180–2191.

Rockman HA, Koch WJ, Lefkowitz RJ (2002) Seven-transmembrane-spanning receptors and heart function. *Nature* 415:206–212.

Rodrigues SM, Bauer EP, Farb CR, Schafe GE, LeDoux JE (2002) The group I metabotropic glutamate receptor mGluR5 is required for fear memory formation and long-term potentiation in the lateral amygdala. *J Neurosci* 22:5219–5229.

Rohrer DK, Desai KH, Jasper JR, Stevens ME, Regula DP Jr, Barsh GS, Bernstein D, Kobilka BK (1996) Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects. *Proc Natl Acad Sci* 93:7375–7380.

Rudy JW, Matus-Amat P (2009) DHPG activation of group 1 mGluRs in BLA enhances fear conditioning. *Learn Mem* 16:421–425.

Sadalge A, Coughlin L, Fu H, Wang B, Valladares O, Valentino R, Blendy JA (2003) alpha 1d Adrenoceptor signaling is required for stimulus induced locomotor activity. *Mol Psychiatry* 8:664–672.

Sahu A, Tyeryar KR, Vongtau HO, Sibley DR, Undie AS (2009) D5 dopamine receptors are required for dopaminergic activation of phospholipase C. *Mol Pharmacol* 75:447–453.

Sara SJ (2009) The locus coeruleus and noradrenergic modulation of cognition. *Nat Rev Neurosci* 10:211–223.

Schafe GE, LeDoux JE (2000) Memory consolidation of auditory pavlovian fear conditioning requires protein synthesis and protein kinase A in the amygdala. *J Neurosci* 20:RC96.

Schutsky K, Ouyang M, Castelino CB, Zhang L, Thomas SA (2011) Stress and glucocorticoids impair memory retrieval via {beta}2-adrenergic, Gi/o-coupled suppression of cAMP signaling. *J Neurosci* 31:14172–14181.

Sibley DR, Monsma FJ Jr (1992) Molecular biology of dopamine receptors. *Trends Pharmacol Sci* 13:61–69.

Stein MB, Kerridge C, Dimsdale JE, Hoyt DB (2007) Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients. *J Trauma Stress* 20:923–932.

Stratton KR, Cole AJ, Pritchett J, Eccles CU, Worley PF, Baraban JM (1989) Intrahippocampal injection of pertussis toxin blocks adenosine suppression of synaptic responses. *Brain Res* 494:359–364.

Tecott LH, Logue SF, Wehner JM, Kauer JA (1998) Perturbed dentate gyrus function in serotonin 5-HT2C receptor mutant mice. *Proc Natl Acad Sci* 95:15026–15031.

Thomas SA, Palmiter RD (1997) Disruption of the dopamine beta-hydroxylase gene in mice suggests roles for norepinephrine in motor function, learning, and memory. *Behav Neurosci* 111:579–589.

Thomas SA, Matsumoto AM, Palmiter RD (1995) Noradrenaline is essential for mouse fetal development. *Nature* 374:643–646.

Tully K, Bolshakov VY (2010) Emotional enhancement of memory: how norepinephrine enables synaptic plasticity. *Mol Brain* 3:15.

Undie AS, Weinstock J, Sarau HM, Friedman E (1994) Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. *J Neurochem* 62:2045–2048.

Waelbroeck M, Taton G, Delhayé M, Chatelain P, Camus JC, Pochet R, Leclerc JL, De Smet JM, Robberecht P, Christophe J (1983) The human heart beta-adrenergic receptors. II. Coupling of beta 2-adrenergic receptors with the adenylyl cyclase system. *Mol Pharmacol* 24:174–182.

Weeber EJ, Atkins CM, Selcher JC, Varga AW, Mirnikjoo B, Paylor R, Leitges M, Sweatt JD (2000) A role for the beta isoform of protein kinase C in fear conditioning. *J Neurosci* 20:5906–5914.

Wei F, Qiu CS, Liauw J, Robinson DA, Ho N, Chatila T, Zhuo M (2002) Calcium calmodulin-dependent protein kinase IV is required for fear memory. *Nat Neurosci* 5:573–579.

Weisstaub NV, Zhou M, Lira A, Lambe E, González-Maeso J, Hornung JP, Sibille E, Underwood M, Itohara S, Dauer WT, Ansorge MS, Morelli E, Mann JJ, Toth M, Aghajanian G, Sealfon SC, Hen R, Gingrich JA (2006) Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. *Science* 313:536–540.

Wilensky AE, Schafe GE, LeDoux JE (2000) The amygdala modulates memory consolidation of fear-motivated inhibitory avoidance learning but not classical fear conditioning. *J Neurosci* 20:7059–7066.

Xu M, Moratalla R, Gold LH, Hiroi N, Koob GF, Graybiel AM, Tonegawa S (1994) Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. *Cell* 79:729–742.